J F Trotter

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. doi Absence of Pneumocystis jiroveci pneumonia in liver transplantation recipients receiving short-term (3-month) prophylaxis
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 1635 N Ursula, B 154, Aurora, CO 80045, USA
    Transpl Infect Dis 10:369-71. 2008
  2. ncbi Transmission of hepatitis C by implantation of a processed bone graft. A case report
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B154, Denver, CO 80262, USA
    J Bone Joint Surg Am 85:2215-7. 2003
  3. ncbi Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper
    J F Trotter
    Division of Gastroenterology Hepatology Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Transpl Infect Dis 5:174-80. 2003
  4. ncbi MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    JAMA 291:1871-4. 2004
  5. ncbi Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation
    James F Trotter
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 10:995-1000. 2004
  6. ncbi Living donor liver transplantation: is the hype over?
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 4200 E, 9th Avenue, B 154, Denver, CO 80262, USA
    J Hepatol 42:20-5. 2005
  7. ncbi Coagulation abnormalities in patients who have liver disease
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B 154 Denver, CO 80262, USA
    Clin Liver Dis 10:665-78, x-xi. 2006
  8. ncbi Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Aliment Pharmacol Ther 22:37-44. 2005
  9. ncbi Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS)
    J Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Dig Dis Sci 50:1356-60. 2005
  10. ncbi Outcomes of donor evaluations for adult-to-adult right hepatic lobe living donor liver transplantation
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, USA
    Am J Transplant 6:1882-9. 2006

Research Grants

Collaborators

Detail Information

Publications70

  1. doi Absence of Pneumocystis jiroveci pneumonia in liver transplantation recipients receiving short-term (3-month) prophylaxis
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 1635 N Ursula, B 154, Aurora, CO 80045, USA
    Transpl Infect Dis 10:369-71. 2008
    ..At our center we have utilized a short-term (3-month) prophylactic regimen with TMP/SMZ for the past decade and report our experience and speculate on the potential widespread application of this approach...
  2. ncbi Transmission of hepatitis C by implantation of a processed bone graft. A case report
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B154, Denver, CO 80262, USA
    J Bone Joint Surg Am 85:2215-7. 2003
  3. ncbi Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper
    J F Trotter
    Division of Gastroenterology Hepatology Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Transpl Infect Dis 5:174-80. 2003
    ..Since we have initiated a prednisone-free immunosuppressive regimen in January 2000, we have noted an extremely low incidence of CMV disease in our cohort of liver transplant recipients. We report our findings here...
  4. ncbi MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    JAMA 291:1871-4. 2004
    ....
  5. ncbi Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation
    James F Trotter
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 10:995-1000. 2004
    ..The selection of laboratory methodologies may have a significant impact on MELD score...
  6. ncbi Living donor liver transplantation: is the hype over?
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 4200 E, 9th Avenue, B 154, Denver, CO 80262, USA
    J Hepatol 42:20-5. 2005
  7. ncbi Coagulation abnormalities in patients who have liver disease
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B 154 Denver, CO 80262, USA
    Clin Liver Dis 10:665-78, x-xi. 2006
    ....
  8. ncbi Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Aliment Pharmacol Ther 22:37-44. 2005
    ..In our cohort of patients with hepatitis-C virus, which is the most common indication for liver transplantation, we have noted higher relative blood levels of tacrolimus compared to patients without hepatitis-C virus...
  9. ncbi Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS)
    J Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Dig Dis Sci 50:1356-60. 2005
    ....
  10. ncbi Outcomes of donor evaluations for adult-to-adult right hepatic lobe living donor liver transplantation
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, USA
    Am J Transplant 6:1882-9. 2006
    ..A large proportion of the patients undergoing liver biopsy have abnormal findings. Our evaluation process failed to identify 4 of 103 who had aborted donor surgeries...
  11. ncbi Documented deaths of hepatic lobe donors for living donor liver transplantation
    James F Trotter
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 12:1485-8. 2006
    ....
  12. ncbi Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory
    J F Trotter
    University of Colorado Health Sciences Center, Denver, CO, USA
    Am J Transplant 7:1624-8. 2007
    ..These data suggest that further review of interlaboratory variation in MELD should be undertaken because of the potential impact on prioritization for liver transplantation...
  13. pmc Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation
    James F Trotter
    Department of Surgery, University of Colorado, Denver, CO 80262, and Department of Transplant Services, Piedmont Hospital, Atlanta, GA, USA
    Transplantation 83:1506-8. 2007
    ....
  14. pmc Outcomes of donor evaluation in adult-to-adult living donor liver transplantation
    James F Trotter
    Department of Surgery, University of Colorado, Denver, CO, USA
    Hepatology 46:1476-84. 2007
    ..Other predictors of donor acceptance included earlier year of evaluation and transplant center...
  15. ncbi Selection of donors for living donor liver transplantation
    James F Trotter
    University of Colorado Health Sciences Center, Denver, CO 80209, USA
    Liver Transpl 9:S2-7. 2003
  16. ncbi Sirolimus in liver transplantation
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Boulder, Colorado 80262, USA
    Transplant Proc 35:193S-200S. 2003
    ..Finally, the potential benefits of antifibrosis and antineoplastic effects of sirolimus in liver transplant recipients will be discussed...
  17. ncbi Expanding the donor pool for liver transplantation
    J F Trotter
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B 158, Denver, CO 80262, USA
    Curr Gastroenterol Rep 2:46-54. 2000
    ..The third way to expand the donor pool is through advances in medical practice such as living-donor liver transplantation and split-liver transplantation...
  18. ncbi Selection of donors and recipients for living donor liver transplantation
    J F Trotter
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 6:S52-8. 2000
    ..3. Use of our current criteria in Colorado for selection of donors and recipients indicated that 15% of recipients could undergo LDLT...
  19. ncbi Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado, Denver, CO 80262, USA
    Transplantation 75:473-6. 2003
    ..In this study, we compare the comprehensive cost of LDLT with that of cadaveric-liver transplantation...
  20. ncbi Combined liver-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent diabetes mellitus
    J F Trotter
    Division of Gastroenterology, University of Colorado Health Sciences Center, Denver 80262, USA
    Transplantation 70:1469-71. 2000
    ..We report successful combined liver-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent diabetes mellitus and review the literature on this topic...
  21. ncbi Adult-to-adult transplantation of the right hepatic lobe from a living donor
    James F Trotter
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 346:1074-82. 2002
  22. ncbi Evaluation of 100 patients for living donor liver transplantation
    J F Trotter
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 6:290-5. 2000
    ..Recipient characteristics and donor availability may limit the widespread use of LDLT. However, careful application of LDLT to patients at greatest risk for dying on the waiting list may significantly reduce waiting list mortality...
  23. ncbi Cancer surveillance following orthotopic liver transplantation
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Gastrointest Endosc Clin N Am 11:199-214. 2001
    ..Many of these patients have an increased risk for gastrointestinal malignancies. This article provides a rational basis for surveillance of gastrointestinal malignancies in the liver transplant recipient...
  24. ncbi Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 8:212-8. 2002
    ....
  25. ncbi Right hepatic lobe donation for living donor liver transplantation: impact on donor quality of life
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 7:485-93. 2001
    ....
  26. ncbi Liver transplantation using sirolimus and minimal corticosteroids (3-day taper)
    J F Trotter
    Division of Gastroenterology, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 7:343-51. 2001
    ..Patient and graft survival rates were identical to those of historical controls. The findings in this report will serve as the basis for a formal trial evaluating the efficacy of sirolimus in liver transplantation...
  27. ncbi Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 7:401-8. 2001
    ....
  28. ncbi Immunosuppression in liver transplantation
    G T Everson
    Division of Gastroenterology and Hepatology and Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
    Minerva Chir 58:725-40. 2003
    ..Ongoing advances in immunosuppressive and antiviral medications will allow tailoring of the immunosuppressive prescription, which undoubtedly will benefit current and future liver recipients...
  29. doi International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure
    Russ Arjal
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 1635 N Ursula, B 154, Aurora, CO 80045, USA
    Clin Liver Dis 13:67-71. 2009
    ....
  30. doi Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course
    Jeffrey Campsen
    Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 14:181-5. 2008
    ..6-50.6 months). In conclusion, recurrent PSC following OLT is a formidable but protracted problem following OLT. Patients may require a second transplant following reemergent disease with reasonable survival benefit...
  31. doi Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal
    Jeffrey Campsen
    Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO 80045, USA
    Liver Transpl 14:1281-6. 2008
    ..In conclusion, outcomes in AIH patients were quite favorable, and none of the patients required retransplantation for recurrent AIH. With a CS minimization approach, one-half of the patients were able to remain CS-free...
  32. ncbi Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications
    Jeffrey C Dunkelberg
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 9:463-8. 2003
    ..The prevalence of wound and hepatic artery complications is not different in liver transplant recipients administered sirolimus as part of a primary immunosuppressive regimen compared with historic controls...
  33. doi Corticosteroid elimination in simultaneous liver-kidney transplantation recipients
    Nicholas K Weber
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Clin Transplant 23:958-63. 2009
    ..While less common in kidney transplant alone recipients (KTA), corticosteroid discontinuation is performed routinely in liver transplantation, raising the question of optimal immunosuppression for SLK recipients...
  34. pmc Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study
    C E Freise
    Department of Surgery, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 8:2569-79. 2008
    ..gt;40). In summary, complication rates were higher after LDLT versus DDLT, but declined with center experience to levels comparable to DDLT...
  35. ncbi Living donor liver transplantation in patients with hepatitis C
    Michael A Zimmerman
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80202, USA
    Liver Transpl 9:S52-7. 2003
    ..3. Potential mechanisms for differences in severity of HCV in LDLT recipients are discussed. 4. LDLT remains a viable treatment option for selected patients with HCV...
  36. pmc Donor morbidity after living donation for liver transplantation
    Rafik M Ghobrial
    Department of Surgery, University of California Los Angeles, Los Angeles, California, USA
    Gastroenterology 135:468-76. 2008
    ..The rate and severity of complications in living donors were investigated in the 9-center Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL)...
  37. ncbi Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma
    Jeffrey Campsen
    University of Colorado Health Sciences Center, Division of Transplant Surgery, Denver, CO 80262, USA
    Expert Opin Pharmacother 8:1275-82. 2007
    ..Herein, the authors review the experience to date with SRL as a primary immunosuppressive agent following OLT, and discuss the clinical implications of SRL-based therapy in OLT recipients with cirrhosis and cancer...
  38. doi Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma
    Michael A Zimmerman
    Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO 80045, USA
    Liver Transpl 14:633-8. 2008
    ..Cumulatively, these data suggest a potential survival benefit with SRL-based therapy in patients undergoing OLT for end-stage liver disease and concomitant malignancy...
  39. ncbi Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience
    Michael A Zimmerman
    Division of Transplant Surgery, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Transpl Int 20:747-53. 2007
    ..Pathologic variables including tumor stage and grade have a significant impact on outcome. Importantly, it seems that TACE and sirolimus had no beneficial effect...
  40. pmc Development of the allocation system for deceased donor liver transplantation
    John M Coombes
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Med Res 3:87-92. 2005
    ..The current system for DDLT remains imperfect but has improved significantly in the past decade. As the number of patients in need of DDLT grows, the system will continue to evolve to meet this increasing demand...
  41. ncbi Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation
    Marcelo Kugelmas
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver 80262, USA
    Liver Transpl 9:727-32. 2003
    ..Length of corticosteroid use did not affect timing or risk of recurrence, and because it has been proven that early corticosteroid withdrawal after liver transplantation is beneficial, we continue to recommend this practice...
  42. ncbi Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients
    Paul H Hayashi
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver 80262, USA
    Liver Transpl 9:737-40. 2003
    ..2 v 19.8 days; P =.01). In conclusion, MELD scores did not predict post-LDLT patient or graft survival at 1 year. However, higher MELD scores (> or =18) were associated with more hospital days during the 3-month post-LDLT period...
  43. ncbi Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection
    Marcelo Kugelmas
    Divisions of Gastroenterology Hepatology, University of Colorado, Denver, CO 80262, USA
    Liver Transpl 9:1159-65. 2003
    ..0006). In conclusion, IS levels decreased significantly in patients responding favorably to anti-HCV therapy. This decrease in IS levels may have a key role in predisposing these patients to ACR...
  44. ncbi Hepatocellular carcinoma extension into the right atrium
    Paul Hayashi
    Hepatology Division, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 9:1225-6. 2003
  45. ncbi The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension
    M Susan Mandell
    Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Anesth Analg 97:1573-7. 2003
    ..Changes in the hepatic venous pressure gradient must be interpreted with caution during desflurane general anesthesia...
  46. ncbi Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD
    Paul H Hayashi
    Hepatology Section, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 10:42-8. 2004
    ..More stringent HCC diagnostic criteria will be required to decrease the effect that misdiagnosis has on organ allocation...
  47. ncbi Review article: adult-to-adult right hepatic lobe living donor liver transplantation
    P H Hayashi
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Aliment Pharmacol Ther 16:1833-41. 2002
    ..This review covers a range of topics, including recipient and donor selection and outcomes, donor risk, controversies and future issues...
  48. ncbi Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation
    Paul H Hayashi
    Division of Gastroenterology, University of Colorado Health Sciences Center, Denver, CO, USA
    Am J Transplant 4:782-7. 2004
    ..This balance is influenced greatly by the MELD system's determination of waiting times for HCC patients...
  49. pmc Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study
    Jeffrey Campsen
    Division of Transplant Surgery, University of Colorado, Aurora, CO 80262, USA
    Liver Transpl 14:1273-80. 2008
    ..Five of the 10 living donors had a total of 7 posttransplant complications. In conclusion, LDLT is rarely performed for ALF, but in selected patients it may be associated with acceptable recipient mortality and donor morbidity...
  50. ncbi Living donor liver transplantation and hepatitis C
    Aaron C Baltz
    University of Colorado, Health Sciences Center, Division of Gastroenterology Hepatology, 4200 E 9th Avenue, Rm B 154 Denver, CO 80262, USA
    Clin Liver Dis 7:651-65, viii. 2003
    ..The optimum clinical approach is to only consider living donor liver transplantation in HCV-infected recipients as a life-saving procedure and to attempt to eradicate HCV before transplantation to prevent recurrent infection...
  51. ncbi Expanding donor options: marginal, living, and split donors
    Richard Foster
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, 4200 E 9th Avenue, Denver, CO 80262, USA
    Clin Liver Dis 11:417-29. 2007
    ..This article discusses the use of the extended criteria donor liver, split-liver, and living-donor liver transplantation...
  52. ncbi Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis
    Tadd Hiatt
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, Colorado 80045, USA
    Am J Med Sci 334:228-30. 2007
    ..Although the incidence of HCC in noncirrhotic hemochromatosis patients is not sufficiently high to warrant routine screening, physicians should be aware that this fatal complication may rarely occur...
  53. doi Preoperative transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic patients undergoing abdominal and pelvic surgeries
    Christine Schlenker
    Division of Gastroenterology, University of Washington Medical Center, Seattle, WA, USA
    Surg Endosc 23:1594-8. 2009
    ..This study aimed to describe the authors' experience with the placement of transjugular intrahepatic portosystemic shunts (TIPS) in patients with cirrhosis to improve surgical outcomes...
  54. doi HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients
    Nicholas K Weber
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, 1635 N Ursula, Aurora, CO 80045, USA
    Dig Dis Sci 55:505-9. 2010
    ..Recurrence prophylaxis is typically long-term hepatitis B immune-globulin (HBIg) and an oral anti-HBV agent. Because of high HBIg costs and improving efficacy of new oral agents, there is increasing interest in HBIg discontinuation...
  55. pmc Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation
    Robert M Merion
    Department of Surgery, University of Michigan, Ann Arbor, MI, USA
    Ann Surg 251:542-9. 2010
    ..To compare rates of hospitalization before and after adult-to-adult living donor liver transplant (LDLT) and deceased donor liver transplant (DDLT)...
  56. ncbi Arterioportal fistula requiring liver transplantation
    Jeffrey D Duman
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 12:1904-5. 2006
  57. ncbi Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients
    Theodore W Perry
    Division of Gastroenterology Hepatology, Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Transplant 21:413-6. 2007
    ..In this study, we report the pharmacokinetic profile of EC-MPS in stable liver transplantation recipients administered a single 720 mg dose...
  58. ncbi A survey of current liver biopsy practice patterns
    Andrew J Muir
    Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Gastroenterol 35:86-8. 2002
    ..To survey clinicians regarding current liver biopsy practice patterns...
  59. doi Vapreotide: a somatostatin analog for the treatment of acute variceal bleeding
    Brett E Fortune
    University of Colorado Denver, Division of Gastroenterology and Hepatology, Academic Office 1, B158, 12631 E 17th Avenue Room 7614, PO Box 6511, Aurora, CO 80045, USA
    Expert Opin Pharmacother 10:2337-42. 2009
    ....
  60. doi Sirolimus conversion for renal preservation in liver transplantation: not so fast
    Geoffrey S Jensen
    Liver Transpl 14:601-3. 2008
  61. ncbi Hepatocellular carcinoma
    Alastair D Smith
    Lancet 363:898-9. 2004
  62. ncbi Living donor liver transplantation and hepatitis C
    Lisa M Forman
    Liver Transpl 10:347-8. 2004
  63. ncbi Single-center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations
    James F Trotter
    Liver Transpl 12:1455-6. 2006
  64. pmc Improvement in survival associated with adult-to-adult living donor liver transplantation
    Carl L Berg
    Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA
    Gastroenterology 133:1806-13. 2007
    ..The aim of this study was to determine whether there is a survival benefit of adult LDLT...
  65. pmc Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates
    Michael B Fallon
    Department of Medicine, University of Alabama, Birmingham, Alabama 35294 0005, USA
    Gastroenterology 135:1168-75. 2008
    ..We assessed the impact of HPS in patients evaluated for liver transplantation...
  66. pmc Clinical risk factors for portopulmonary hypertension
    Steven M Kawut
    Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH 8E, Room 101, New York, NY 10032, USA
    Hepatology 48:196-203. 2008
    ..24, 95% confidence interval 0.09-0.65, P = 0.005) of portopulmonary hypertension. The severity of liver disease was not related to the risk of portopulmonary hypertension...
  67. ncbi Treatment of chronic HCV in advanced liver disease: unmet challenges, reason for optimism
    Geoffrey S Jensen
    J Hepatol 47:441-3. 2007
  68. ncbi Erythrocytosis in a patient with hepatocellular carcinoma
    James F Trotter
    J Clin Gastroenterol 35:365-6. 2002
  69. ncbi Immunosuppression: evolution in practice and trends, 1993-2003
    Ron Shapiro
    Thomas E Starzl Transplant, University of Pittsburgh, Pittsburgh, PA, USA
    Am J Transplant 5:874-86. 2005
    ....
  70. ncbi Torulopsis glabrata fungemia from infected transjugular intrahepatic portosystemic shunt stent
    Thomas W Brickey
    Division of Gastroenterology, Department of Medicine, University of Colorado Health Sciences Center, Denver, 80220, USA
    J Vasc Interv Radiol 16:751-2. 2005
    ..This report describes the successful long-term survival of a patient with Torulopsis TIPS stent infection...

Research Grants4

  1. Adult to Adult Living Donor Liver Transplantation Cohor*
    James Trotter; Fiscal Year: 2007
    ..With completion of the LDLT Cohort Study, the medical community will have a much clearer understanding of the impact of this important procedure on liver transplantation, LDLT recipients and LDLT donors. ..